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ABSTRACT
Products of the Steroid Receptor RNA Activator
gene (SRA1) have the unusual property to modulate
the activity of steroid receptors and other transcrip-
tion factors both at the RNA (SRA) and the protein
(SRAP) level. Balance between these two genetically
linked entities is controlled by alternative splicing
of intron-1, whose retention alters SRAP reading
frame. We have previously found that both fully-
spliced SRAP-coding and intron-1-containing non-
coding SRA RNAs co-exist in breast cancer cell
lines. Herein, we report a significant (Student’s
t-test, P<0.003) higher SRA–intron-1 relative
expression in breast tumors with higher progester-
one receptor contents. Using an antisense oligori-
bonucleotide, we have successfully reprogrammed
endogenous SRA splicing and increased SRA RNA–
intron-1 relative level in T5 breast cancer cells. This
increase is paralleled by significant changes in the
expression of genes such as plasminogen urokinase
activator and estrogen receptor beta. Estrogen reg-
ulation of other genes, including the anti-metastatic
NME1 gene, is also altered. Overall, our results
suggest that the balance coding/non-coding SRA
transcripts not only characterizes particular tumor
phenotypes but might also, through regulating the
expression of specific genes, be involved in breast
tumorigenesis and tumor progression.
INTRODUCTION
The Steroid Receptor RNA Activator (SRA) was ﬁrst
identiﬁed in 1999 as a non-coding RNA speciﬁcally
co-activating steroid receptors (1). Through mutation ana-
lysis, the authors unequivocally showed in their original
report that the core region, corresponding to sequences
encompassing exons 2 to 5 (Figure 1A), was necessary
and suﬃcient for SRA to act as co-activator (1). Several
studies have since shed light on SRA’s mechanisms of
action [reviewed in (2)]. Brieﬂy, it is believed that SRA
acts embedded in ribonucleo-protein complexes recruited
to the promoter of regulated genes. These complexes may
contain positive regulators, such as the steroid receptor
co-activator 1 (SRC-1), the DExD/H box family of
RNA-helicase members p68 and p72, or the pseudouridine
synthases Pus1p and Pus3p. Negative regulators, such as
SMRT/HDAC1 Associated Repressor Protein (Sharp)
and the recently identiﬁed SRA stem-loop interacting
RNA binding protein (SLIRP), can also interact with
SRA to decrease its activity (3,4).
If SRA was originally thought to speciﬁcally increase
the activity of steroid receptors, further data have subse-
quently demonstrated that this RNA can also co-activate
non-steroid nuclear receptors as well as other transcrip-
tion factors such as MyoD (2). SRA has therefore a
wider role than ﬁrst anticipated and likely participates in
signalling pathways still to be uncovered.
Additional SRA transcripts, almost identical to the
original SRA and containing a full core sequence, have
now been described (Figure 1B). As a result of gene poly-
morphism (5) they can however contain point mutations
in exon-2 (SRA2) or an additional codon in exon-3
(SRA3). These transcripts can be divided in two cate-
gories: coding and non-coding SRAs. Coding isoforms
have an extended exon-1, which contains two translation
initiating methionine codons (Figure 1B). These coding
SRAs have been proven to encode an endogenous SRA
protein (SRAP) in several tissues including breast,
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tions of SRAP remain to be fully elucidated (2), indepen-
dent reports suggest that this protein also regulate steroid
receptor signalling, potentially as co-activator (8,9), or as
a repressor (10,11).
Non-coding SRA transcripts, generated through alter-
native splicing of intron-1, have also been characterized
(2,12). These transcripts contain either a full (FI) or a
partial (PI) intron-1 sequence (Figure 1B). The partial
intron retention results from the use of an alternative 30
acceptor site located 60bp upstream of exon-2 (12). Non-
coding SRAs can also result from the concomitant use of
an alternative 50 donor site (located 15bp upstream of the
end of exon-1) and the alternative 30 acceptor site (AD).
All these diﬀerent splicing events, which occur indepen-
dently of the isoform considered (i.e. SRA1, SRA2 or
SRA3), either shift SRAP open reading frame or intro-
duce premature stop codons. The resulting alternatively
spliced SRA RNAs are therefore unable to encode for
SRAP.
It should be stressed that both fully- and alternatively-
spliced SRA transcripts contain the functional core
sequence. They can therefore act as transcriptional
co-activators. The additional ability of fully-spliced SRA
RNAs to encode for SRAP creates a peculiar level of
functional complexity to the products of the SRA1 gene.
We have shown that both coding and non-coding SRA
coexist in breast cancer cells (12). Interestingly, their rela-
tive expression varies between breast cancer cells lines with
diﬀerent phenotypes (12). In particular, we have observed
that invasive breast cancer cell lines (MDA-MB-231,
MDA-MB-468) expressed higher relative levels of non-
coding SRA than ‘closer to normal’ MCF-10A1 breast
cells. This suggests that a balance ‘tipped’ toward the pro-
duction of non-coding SRA RNA in breast cells might
be associated with growth and/or invasion properties.
This further raises the possibility that modifying the bal-
ance between these transcripts could trigger meaningful
events in breast cancer cells.
To further explore the potential relevance of the balance
coding/non-coding SRAs in breast cancer, we have herein
investigated SRA–intron-1 relative expression in a small
cohort of invasive breast tumors. Using an antisense oli-
goribonucleotide designed to target SRA exon-1/intron-1
junction, we have also assessed our ability to artiﬁcially
alter the balance coding/non-coding SRA transcripts in
T5 breast cancer cell line.
MATERIALS AND METHODS
Cells and tumor tissues
T5 breast cancer cells were kindly provided by Murphy
(13). Cells were cultured in DMEM (GIBCO, Grand
Island, NY) supplemented with 5% fetal bovine serum
(CANSERA, Rexdale, ON), penicillin (100 units/ml),
streptomycin (100mg/ml) (GIBCO, Grand Island, NY)
and 0.3% glucose. Cells were grown in a 378C humidiﬁed
incubator with 5% CO2.
Thirty-two tumor samples, with a wide range of estro-
gen receptor (ER, from 6.3 to 247fmol/prot, median
=82.5fmol/prot) and progesterone receptor (PR, from
12.2 to 444fmol/prot, median=38.5fmol/prot) levels,
were selected from the Manitoba Breast Tumor Bank
(14), which operates with the approval of the Faculty
of Medicine, University of Manitoba, Research Ethics
Board.
Oligonucleotide treatment
20-O-Methyl-oligoribonucleotide phosphorothioate
20-mers anti-sense to the 50-splice site of SRA intron-1
(SRA–AS, 50-ACCCGGCUUCACGUACAGCU-30) and
to the 50-splice site of a modiﬁed b-globin intron (bgl–AS,
50-ACCUGCCCAGGGCCUCACCA-30) were synthe-
sized and puriﬁed by Trilink Biotechnologies, Inc.
(San Diego, CA). Fluorophore (Indocarbocyanine-Cy3
and 5-Carboxyﬂuorescein_FAM) conjugated versions
(SRA–AS–Cy3 and bgl–AS–FAM) were also obtained
from Trilink Biotechnologies, Inc. Transfections were per-
formed using DMRIE-C reagent (16mg/ml; Invitrogen,
Carlsbad, CA) according to the manufacturer’s directions
using concentrations ranging from 0 to 0.5mM. It should
be noted that when no oligonucleotide was added (mock),
cells were also treated with DMRIE-C reagent. Five hours
post-treatment, transfection medium was replaced with
fresh medium, and cells were cultured for the indicated
times. For oligonucleotide and minigene co-transfections,
T5 cells were plated at 3.5 10
5cells per well in 6-well
plates and co-transfected with 1.65mg of SRA minigene
and 0.05, 0.1 or 0.5mM oligoribonucleotides using
DMRIE-C reagent (16mg/ml, Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Medium
containing the transfection complex was replaced by
DMEM containing 5% FBS 5h post transfection.
Fluorescent microscopy
Cells were cultured on coverslips and transfected with
SRA–AS–Cy3 or bgl–AS–FAM at the indicated concen-
trations and times post-treatment. Coverslips were then
brieﬂy washed with PBS and cells were ﬁxed with 3.7%
formaldehyde in PBS for 15min at room temperature.
Cover-slips were then rinsed with PBS and cells permea-
bilized with 0.2% Triton-X100 in PBS for 1–2min prior
to staining nuclei with 1mg/ml 40,6-diamidino-2-
-phenylindole-dihydrochloride (Dapi). Coverslips were
mounted with FluorSave
TMReagent (Calbiochem, La
Jolla, CA). Fluorescent images were captured with an
Eclipse E1000 epiﬂuorescent microscope (Nikon), digi-
tized with ACT-1 software (v.2.63; Nikon) and merged
images were generated with Photoshop 6.0 (Adobe).
RT–PCR and triple-primer-PCR (TP-PCR)
Total RNA was extracted from cells or frozen tumor
tissue sections using Trizol
TM reagent (Gibco BRL,
Grand Island, NY) and subjected to DNase treatment
(Promega, Madison WI) as previously described (12,15).
Half a microgram of total RNA was reverse transcribed in
a ﬁnal volume of 30ml using Moloney Murine Leukemia
Virus (M-MLV) reverse transcriptase and random hexam-
ers as previously reported (5). One and a half microliters
of reverse-transcription mixture was ampliﬁed in a ﬁnal
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8.5), 15mM [NH4]
2SO4, 1.5mM MgCl2, 0.2mM of each
dNTPs, 4ng/ml of each primer (two or three primers for
RT–PCR and TP-PCR, respectively), 1 unit of Platinum
Taq DNA polymerase (Invitrogen Carlsbad, CA) and
10nM a
 32P dCTP. Each PCR consisted of a 5min pre-
incubation step at 948C followed by 30 cycles of ampliﬁ-
cation (30s at 948C, 30s at 608C and 30s at 728C). The
sequences of primers used are detailed in Supplementary
Table S1.
Radio-labeled PCR products were then separated on
denaturating poly-acrylamide/urea gels as previously
described (15). Following electrophoresis, the gels were
dried and exposed 30min to a Molecular Imager
TM-FX
Imaging screen (Bio-Rad, Hercules, CA). Exposed
screen was then scanned using a Molecular Imager
TM-
FX (Bio-Rad, Hercules, CA), which allows the subsequent
quantiﬁcation of each observed signal.
The identity of all PCR products obtained has been con-
ﬁrmed following subcloning and sequencing as described
previously (12,16).
Quantification and normalization of PCR signals
PCR signals were quantiﬁed using a Molecular Imager
TM-
FX (Bio-Rad, Hercules, CA) as previously described
(15). For each TP-PCR experiment (Figures 2 and 4),
the relative amount of fully spliced and intron-1 retained
SRA of each sample was ﬁrst expressed as the percentage
of the total signal measured following ampliﬁcation (12).
For tumor cases (Figure 2), the percentage of intron-1
retained signal was then divided by the average intron-1
retained percentage observed in T5 cells always analyzed
in parallel (arbitrary unit). For Figure 2C, each dot repre-
sents the average of three independent experiments.
Diﬀerences between tumor subgroups were tested using
the Student’s t-test (two-tailed). For Figure 4, the average
obtained in Mock transfected cells was used as reference
(corresponding to 1a.u.). For each time and experiment,
diﬀerences with the signal obtained in mock cells were
tested using the Student’s t-test (two-sided).
Western blot analysis
Total cell lysates were analyzed and SRAP was detected
using rabbit anti-SRAP 743 (Bethyl Laboratories Inc,
Montgomery, TX) antibody in conjunction with a goat
anti-rabbit HRP (Sigma, St Louis, MO) antibody at dilu-
tions of 1/1000 and 1/3000, respectively, as described (6).
Real-time PCR
All PCR reactions were performed in an iCycler iQ
TM
Real-Time PCR Detection System (Bio-rad). For each
PCR run, a master-mix was prepared on ice containing
2.5mM MgCl2, 2.5mM each dATP, dCTP, dGTP and
dTTP, 0.1mg each primer, 0.2x SYBRGreen1
(Molecular Probes, Inc.), 5nM Fluorescein, 2.5%
DMSO, 1  PCR Reaction Buﬀer (Invitrogen, Carlsbad,
CA) and 1 unit of Platinum Taq DNA polymerase
(Invitrogen, Carlsbad, CA) (Figure 5). Two and a half
microliters of each RT sample was added to 40ml of PCR
master-mix. The thermal cycling conditions comprised an
initial denaturation step at 958C for 10min, then 40 cycles
at 958C for 30s, 608C for 45s and 728C for 30s. Primers
used are detailed in Supplementary Table S1. Three experi-
mentswereperformed.Foreachtreatmentandexperiment,
the number of cycles needed to reach the deﬁned cycle
threshold forfully splicedandintron-1 alternatively spliced
was ﬁrst corrected for the number of cycles leading to the
average 36B4 threshold cycle to obtain a normalized cycle
number. The average number of normalized cycles for
intron-1 retained and fully spliced RNA from the three
experiments performed with no oligo (Mock) was then cal-
culated to obtain intron-1 average mock and fully spliced
average mock. For each treatment and experiment, the
normalized cycle number of intron-1 retained and fully
spliced SRA RNA was then subtracted from intron-1 aver-
age mock and fully spliced average mock, respectively, to
get the number of cycle diﬀerence between treatments
(Ct) and establish the standard deviations. A Ct of
+1 represents a 2
1=2 fold increase in expression, whereas
aCtof 2representsa2
2=4-folddecreaseinexpression.
DiﬀerencesbetweenMockandoligotreatmentsweretested
using the Student’s t-test (two-sided).
Real-time PCR-array
Half a microgram of RNA was reverse transcribed
using ReactionReady
TM First Strand cDNA synthesis
Kit (SuperArray Bioscience Corp., Frederick, MD) and
applied to Breast Cancer and Estrogen Receptor
RT
2Proﬁler
TM PCR arrays (SuperArray Bioscience
Corp., Frederick, MD) as detailed by the manufacturer
(Figures 7 and 8). For Figure 7, four experiments were
performed. For each treatment (SRA–AS and bgl–AS),
gene and experiment, the number of cycles needed
to reach the deﬁned threshold was normalized to the
b-actin signal (ACTB) to obtain the corrected cycle num-
bers. For each gene the corrected cycle number per SRA–
AS treatment was then subtracted from the reference
gene–bgl–AS treatment to get the number of cycle diﬀer-
ence between treatments (Ct) and establish the standard
deviations. Diﬀerences between gene expression upon
SRA–AS and bgl–AS treatments were tested using the
Student’s t-test (two-sided). Levels of expression presented
in Table 1 were calculated as follow. If Ct was higher
than or equal to 0, expression corresponds to 100 2
Ct
whereas when Ct is lower than 0 (i.e. negative), expres-
sion corresponds to 100/2
 Ct.
For Figure 8, cells were treated with SRA–AS or bgl–
AS as indicated earlier. Twenty-four hours post treatment,
medium was changed to medium without serum for an
additional 24h. Cells were then treated with E2 10
 8M
or vehicle alone (ethanol 1/1000) for 4h before extraction
of total RNA and SuperArray analysis. Three experiments
were performed. For all treatment (SRA–AS and bgl–AS
with Ethanol or E2), gene and experiment, the number
of cycles needed to reach the deﬁned threshold was ﬁrst
normalized to the b-actin signal (ACTB) to obtain the
corrected cycle numbers. For each gene, the corrected
cycle number following E2 treatment was then subtracted
from the Ethanol treatment to get an arbitrary measure-
ment of E2 action: A Ct(Eth/E2)=1 corresponds to
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1=2-fold increase in expression, whereas a Ct(Eth/
E2)= 1 represents a 2
1=2-fold decrease in expression.
Diﬀerences between gene expressions upon treatments
were tested using the Student’s t-test (two-sided).
Cell proliferation assay
Cell viability/proliferation was measured using CellTiter
96Aqueous One Solution Reagent (Promega Co.,
Madison, WS) as previously described (17). Brieﬂy, T5
cells were treated as described earlier with anti-sense
oligos or not (mock). Twenty-four hours later, cells
(3 10
3cells) were re-seeded in 96 wells dishes in
5%FBS–DMEM. Twenty-four hours after re-seeding
(48h post oligo treatment), T0 measurements were
taken. Media was changed every two days after T0. All
time-point measurements were taken by adding, at various
times (T0, 1, 3, 5 days), 40ml of CellTiter 96AQueous One
Solution Reagent to each well containing 200ml medium,
followed by incubation for 3h at 378C. The absorbance
was then recorded at 490nm with 96-well plate reader
(SpectraMax 190, Molecular Devices, Sunnyvale, CA.)
All time point measurements were ﬁrst blanked to the
appropriate media not exposed to cells. For each experi-
ment (performed in quadruplicate) the average of absor-
bance at T0 was calculated and deduced from each
experimental points. For each point, the resulting mean
of two independent experiments (expressed as Viability,
a.u) and standard deviations were plotted using Prism 5
(GraphPad software, Inc, La Jolla, CA). Diﬀerences were
tested using the Student’s t-test (two-sided).
RESULTS
Higher SRA–intron-1 relative expression in breast tumors
with higher progesterone receptor contents
Thirty-two diﬀerent human breast tumors were selected
from the Manitoba Breast Tumor Bank. These tumors
spanned a wide range of estrogen receptor alpha (ER)
and progesterone receptor (PR) levels, as assessed by
ligand binding assay. Total RNA was extracted from
frozen tumor tissue sections, reverse-transcribed and
the relative expression of non-coding SRA transcripts
containing intron-1 analyzed by radioactive TP-PCR,
as described in the ‘Materials and Methods’ section.
TP-PCR, which relies on the use of three primers during
the PCR reaction, has been previously validated to assess
the relative proportion of transcripts sharing a common
extremity but diﬀering in the other (12,16,18). As illu-
strated Figure 2A, the lower primer (primer E) recognizes
the common exon 3 sequence, whereas the upper primers
(C and D) are designed to recognize intron-1 and exon-1
sequence, speciﬁc of non-coding and coding SRA tran-
scripts, respectively. Two PCR products (377–380 and
360–363bp), corresponding respectively, to SRA tran-
scripts containing intron-1 sequences (FI, PI and AD in
Figure 1B) or fully spliced (FS), are expected. The poten-
tial 3bp size diﬀerence corresponds to the additional
codon speciﬁc for SRA3 isoform and located in the ampli-
ﬁed part of exon-3 analyzed (Figure 1B). PCR products
corresponding to both coding and non-coding transcripts
were detected in all samples analyzed (Figure 2B). For
each sample, signals were quantiﬁed and the relative pro-
portion of SRA intron-1 containing RNA was expressed
in arbitrary unit (a.u, Figure 2C). Relative level of this
transcript varies from one case to another (min: 0.71a.u,
max: 1.61a.u, median 1.10a.u). No diﬀerence was found
in the relative expression of non-coding SRA when com-
paring cases with low ER (n=16, ER<82.5fmol/mg
prot., intron-1 median: 1.04a.u) and high ER (n=16,
ER>82.5fmol/mg prot., intron-1 median: 1.14a.u.).
In contrast, a signiﬁcant (Student’s t-test, two-sided,
P<0.003) higher intron-1 retention was observed in sam-
ples with high PR (n=16, PR>38.5fmol/mg prot.,
intron-1 median: 1.27a.u.), than with low PR (n=16,
PR<38.5fmol/mg prot., intron-1 median: 1.02a.u.).
Altering intron-1 splicing events using a modified
anti-sense oligoribonucleotide
Reprogramming splicing events through transfection of
modiﬁed antisense oligoribonucleotides targeting exon–
intron junctions to interfer with donor or acceptor splicing
sites has been successfully achieved in diﬀerent systems
(19,20). We hypothesized that an oligonucleotide comple-
mentary to the junction exon-1–intron-1 could reprogram
the fate of pre-messenger RNA and lead to the production
of more alternatively spliced non-coding SRA transcripts
Figure 3.
Figure 1. Genomic structure of SRA1, coding and non-coding SRA
transcripts. (A) SRA1 gene, located on chromosome 5q31.3, consists
of ﬁve exons (boxes) and four introns (plain lines). The originally
described non-coding SRA sequence (AF092038) contains a core
sequence (light gray), necessary and suﬃcient for SRA RNAs to act
as co-activators. (B) Three coding isoforms have been identiﬁed (SRA1,
SRA2, SRA3), which contain an extended 50-extremity containing two
AUG initiating codons (vertical white bars in exon 1). The stop codon
of the resulting open reading frames (236/237 aa) is depicted by a black
vertical bar in exon 5. Black stars in exons 2 and 3 correspond to a
point mutation (position 98 of the core: U to C) and a point mutation
followed by a full codon (position 271 of the core: G changed to
CGAC), respectively (5). Three non-coding SRA isoforms containing
a diﬀerentially-spliced intron-1 have been characterized FI, full intron-1
retention; PI, partial intron-1 retention; AD, alternative 50 donor and
partial intron retention (12). Thick straight line, 60bp of intron 1
retained in PI.
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might be suitable to block SRA intron-1 donor site and
ultimately alter SRA intron-1 splicing events, we initially
used a previously described artiﬁcial SRA– -globin mini-
gene model (12). Two diﬀerent 20-O-methyl-modiﬁed anti-
sense oligoribonucleotide phosphorothioate 20-mers were
designed to recognize the splice donor sites of b-globin
(bgl–AS) and SRA intron-1 (SRA–AS), present on this
mini-gene (Supplementary Figure S1). We ﬁrst established
that both SRA–AS and bgl–AS similarly entered and
remained in T5 cells (Supplementary Figure S2). We
then demonstrated that SRA–AS oligoribonucleotide, as
opposed to bgl–AS, had the ability to interfere with SRA
intron-1 donor site and promoted SRA intron-1 retention
within transcripts originating from our artiﬁcial SRA
minigene (Supplementary Figure S3).
The proportion of endogenous SRA transcripts retaining
intron-1 is increased following treatment of T5 cells
with SRA–AS
To further determine if the introduction of SRA–AS could
also alter the balance of endogenous coding and non-
coding SRA RNAs, dose and time dependence experi-
ments were performed and the relative proportion of
SRA intron-1 retention assessed by triple-primer PCR
(TP-PCR). T5 cells were transfected with increasing con-
centrations of either SRA-AS or bgl-AS oligoribonucleo-
tides and total RNA analyzed by TP-PCR as described
earlier. Co-ampliﬁcation of two products, migrating
at an apparent size of 377 and 360bp, occurred
(Figure 4A). These products were found, following
sequencing, to correspond to the expected non-coding
(containing intron-1) and coding (fully spliced) SRA tran-
scripts. No products were ampliﬁed when RNA was not
reverse-transcribed, conﬁrming that no DNA could possi-
bly be ampliﬁed in this assay. Signals were quantiﬁed and
SRA intron-1 relative levels expressed in arbitrary unit as
described in the ‘Materials and Methods’ section. A dose-
dependent shift towards more intron-1 retention was
observed in T5 cells when treated with SRA–AS. At
the highest concentration tested of 0.5mM, which corre-
sponded to a 100% transfection eﬃciency (Supplementary
Figure S2), SRA–AS led to an approximate 4-fold
increase in the relative amount of intron-1 retention
(Figure 4A, 0.5mM SRA–AS), as compared to mock
transfected control (Figure 4A, 0). As expected, no eﬀect
was observed on the proportion of endogenous intron-1
retaining SRA RNAs when cells were transfected with
equivalent amounts of bgl–AS oligoribonucleotides
(Figure 4A, 0.05mM bgl–AS). bgl–AS oligonucleotides
have been used as negative controls in subsequent
experiments.
Time course experiments similarly performed with no
oligoribonucleotides (Mock), 0.5mM SRA–AS or 0.5mM
bgl–AS oligoribonucleotides, revealed a signiﬁcant (n=5,
p<0.05, Student’s t-test) increase (2.5 0.6 SD fold)
in relative intron-1 retention at t: 24h upon SRA–AS
Figure 2. TP-PCR ampliﬁcation of coding and non-coding SRA
mRNAs in breast cancers. (A) Principle: three primers are used
during the PCR ampliﬁcation. The lower primer (E) is common to
the two sequences whereas, the upper D and C primers are speciﬁc
for exon-1 (gray) and intron-1 (black), respectively (12). Triple-primer
PCR will lead to an intron-1 or Fully spliced (FS) products, corre-
sponding to non-coding and coding SRA RNAs, respectively. (B)
RNA from frozen tissue sections (1–12) and from T5 as well as
MDA-MB-468 (MD) cells was reverse transcribed and ampliﬁed by
TP-PCR as described in ‘Materials and Methods’ section. radio-labeled
PCR products, run on an acrylamide gel, are visualized using a Biorad
Phosphorimager. (C) Signals from three experiments have been quanti-
ﬁed and the average relative proportion of non-coding SRA RNA
expressed in arbitrary unit (intron-1a.u) as detailed in the ‘Materials
and Methods’ section has been graphed for each tumor. For analysis
purposes, tumors have been grouped according to their ER levels:
lower and higher than the median; or according to their PR levels:
lower and higher than the median. The horizontal bar indicates the
median of intron-1 values for each subgroup. Diﬀerences have been
tested using the Student’s t-test two-tailed.
Figure 3. Principle: an oligonucleotide complementary to the junction
exon-1/intron-1 is designed to interfere with the proper splicing of SRA
pre-messenger. As a result, a higher proportion of alternatively spliced
transcripts (containing Full—FI- or partial—PI-intron-1 retention, or
resulting from the use of an alternative donor site (AD) as deﬁned
Figure 1) relative to the fully spliced (FS) should be observed.
4522 Nucleic Acids Research, 2009, Vol. 37,No. 13treatment (Figure 4B, 24h SRA–AS). A maximal 3.5-fold
average increase in the relative level of intron-1 retention
was observed at t: 48h (Figure 4B, 48h SRA–AS) over
that observed for time-matched mock transfected cells.
This eﬀect is maintained, albeit decreased at t: 72h when
levels of intron-1 retention have returned to that of sam-
ples at t: 24h. As expected, bgl–AS oligoribonucleotide
transfection had no eﬀect in promoting endogenous
SRA intron-1 retention in T5 cells.
Increased relative expression of non-coding SRA transcripts
corresponds to both an increase in intron-1 containing
SRA RNAs and a decrease in the levels of fully
spliced SRA RNA
To clarify whether the relative increase in non-coding
SRA RNAs expression observed by TP-PCR resulted
from an increase in intron-1 retaining RNA, a decrease
in fully spliced RNA or both, we assessed the expression
of these SRA RNAs by real-time PCR. T5 cells were trea-
ted with no oligoribonucleotides (Mock), SRA–AS or bgl–
AS oligoribonucleotides and RNA extracted and reverse-
transcribed 24h post-treatment. Following ampliﬁcation
with a lower primer annealing to exon-3 and upper pri-
mers annealing to either intron-1 or exon-1, the percentage
change in the level of intron-1 retained or fully spliced was
quantiﬁed in three independent experiments, as described
in the ‘Materials and Methods’ section (Figure 5). A sig-
niﬁcant (P<0.05, Student’s t-test) average increase of
90% (corresponding to a Ct of 0.92) in the expression
of SRA intron-1 retaining RNA was observed in cells
treated with SRA–AS as compared to mock transfection.
Conversely, a signiﬁcant decrease of 70% (corresponding
to a Ct of  1.82) in fully spliced SRA RNA expression
was observed. As expected, no eﬀect of bgl–AS oligoribo-
nucleotides on either intron-1 retaining or fully spliced
SRA levels was observed.
Decrease of endogenous SRAP in T5 cells treated with
0.5mM SRA–AS
T5 cells were treated with either SRA–AS or bgl–AS for
24, 48 and 72h and SRAP expression assessed by Western
blot as detailed in the ‘Materials and Methods’ section.
Figure 4. Dose and time dependence analysis. (A) T5 cells were treated
with increasing amounts (0, 0.05, 0.1, 0.5mM) of SRA-AS or control
oligos (bgl-AS). At t: 24h, total RNA was extracted, reverse-tran-
scribed and ampliﬁed by TP-PCR as described in ‘Material and meth-
ods’ section. Samples were separated on PAGE gel and visualized using
a Molecular Imager
TM-FX. SRA-AS-RT- correspond to RNAs from
SRA-AS ampliﬁed without reverse-transcription. Signals corresponding
to intron-1 and FS were quantiﬁed and the proportion of intron-1
retention expressed in arbitrary unit (a.u) as described in ‘Materials
and Methods’ section. (B) T5 cells were treated with no oligonucleotide
(Mock), 0.5mM of SRA–AS or 0.5mM bgl–AS. At t: 24, 48 and 72h,
total RNA was extracted, reverse-transcribed and ampliﬁed by TP-PCR
as described in ‘Material and methods’ section. Samples were separated
on PAGE gel and visualized using a Molecular Imager
TM-FX. Signals
corresponding to intron-1 and FS were quantiﬁed and the proportion
of intron-1 retention expressed in arbitrary unit (a.u) as described in
‘Materials and Methods’ section. Bars represent the average value of
ﬁve independent experiments normalized to values obtained for mock
transfection at a given time point. Error bars represent standard devia-
tion.
 Correspond to P-values lower than 0.05 (Student’s t-test).
Figure 5. Real-time PCR quantiﬁcation of intron-1 retaining and fully
spliced SRA RNAs expression following treatment of T5 cells. T5 cells
were treated with no oligoribonucleotide (Mock, white circle), 0.5mM
of SRA–AS (orange circle) or 0.5mM bgl–AS (blue circle). At t:2 4 h ,
total RNA was extracted, reverse-transcribed and analyzed by real-time
PCR as described in ‘Material and methods’ section. Three experiments
were performed and for each treatment, Ct has been calculated as
described in the ‘Materials and Methods’ section. Dots represent the
average Ct for each treatment whereas bars correspond to standard
deviations. Asterisk indicate a signiﬁcant diﬀerence (Student’s t-test,
two-sided) in the corresponding SRA (intron-1 alternatively spliced or
fully spliced) expression between mock and oligo-transfected cells.
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treated cells can be seen after 24h (Figure 6). In contrast,
lower levels of SRAP protein are seen after 48 and 72h of
SRA–AS oligoribonucleotide treatment. As expected, bgl–
AS oligoribonucleotide does not appear to have any eﬀect
on SRAP levels.
Modulation of the balance coding/non-coding endogenous
SRA RNAs alters gene expression in T5 breast cancer cells
To establish whether this artiﬁcial alteration of the bal-
ance between coding/non coding SRA1 RNAs impacts on
gene expression, total RNA from T5 cells transfected with
SRA–AS or bgl–AS oligoribonucleotides was extracted
and analyzed 24h post-transfection by real-time quantita-
tive PCR using a Breast Cancer and Estrogen Receptor
Signaling RT
2 Proﬁler
TM PCR Array (SuperArray
Biosciences USA) as described in the ‘Materials and
Methods’ section. This technology consists of ready-to-
use PCR plates with each well containing an optimized
pair of primers corresponding to a series of known
genes. It provides the fastest way to interrogate the
eﬀect of a given treatment on genes historically linked to
diﬀerent pathways or pathologies (21). The expression of
57 genes was evaluated in cells treated with SRA–AS and
bgl–AS oligoribonucleotides and diﬀerences in expression
assessed using the Student’s t-test (see Table 1 for a full
description of the genes assessed and the results obtained).
The expression of 51 genes remained constant upon SRA–
AS treatment (Figure 7). The expression of ﬁve genes was
however signiﬁcantly increased. A strong increase
(Ct=2.87, corresponding to a 729% increase in the
expression compared to the control) in the expression of
the urokinase plasminogen activator PLAU, gene inti-
mately linked to invasion mechanisms (22), was observed.
Similarly, enhanced levels (Ct=1.73, corresponding to
a 331% increase in the expression compared to the
control) of estrogen receptor beta mRNA (ESR2) was
also found. Expression of Stanniocalcin 2 (STC2), vascu-
lar endothelial growth factor (VEGF) and Thrombospon-
din 1 (THBS1) was signiﬁcantly increased, although to a
lesser extent.
Modulation of the balance coding/non-coding endogenous
SRA RNAs alters the response to estrogen of T5
breast cancer cells
The modiﬁcation of the expression of estrogen receptor
beta together with the known importance of estrogen sig-
naling in breast cancer led us to investigate the eﬀect of
altering the balance coding/non-coding SRA RNAs on the
response of T5 breast cancer cells to estrogen. T5 cells
were transfected with bgl–AS or SRA–AS oligoribonu-
cleotides and treated 48h later with vehicle (ethanol) or
E2 (10
 8M) for a period of 4h, as described in the
‘Materials and Methods’ section. The expression of the
57 genes listed in Table 1 has been assessed as described
earlier. Estradiol treatment of control cells pre-treated
with bgl–AS oligoribonucleotide signiﬁcantly altered
the expression of 10 genes (Figure 8A). Nine genes
(B-cell lymphoma 2: BCL2, Non-metastatic cells protein:
NME1, Thrombospondin 1: THBS1, Trefoil factor 1:
TFF1, Transforming growth factor alpha: TGFA,
Deleted in liver cancer 1: DLC1, Keratin 18: KRT18,
Serpin peptidase inhibitor 3: SERPINA3, Fas, Catenin
beta 1: CTNNB1) are up-regulated whereas a single gene
(Fibronectin Leucine-rich transmembrane protein 1:
FLRT1) is downregulated. Expression of only ﬁve of the
up-regulated genes (BCL2, THBS1, TFF1, TGFA and
DLC1) remain signiﬁcantly increased when cells are pre-
treated with SRA–AS oligoribonucleotide (Figure 8B).
In these latter conditions, estradiol treatment also led to
a signiﬁcantly increase in Heat shock 27kDa protein 1
(HSPB1) and Cathepsin D (CTSD) expression and a
decrease in Nuclear transcription factor Y-beta (NFYB)
and Mucin 1 (MUC1) mRNA levels. Interestingly, a sig-
niﬁcant diﬀerence in estrogen eﬀect when comparing
directly SRA–AS or bgl–AS oligoribonucleotides pre-
treatment is observed for NME1, KRT18, FAS,
CTNNB1 and FLRT1 (Figure 8 C).
Modulation of the balance coding/non-coding endogenous
SRA RNAs alters T5 breast cancer cells growth
To further assess the relevance of the balance coding/non-
coding SRA transcripts, we have compared the viability of
cells treated with SRA–AS, bgl–AS or without oligonu-
cleotides (Mock). Cells were treated as described earlier,
re-seeded after 24h and allowed to grow in normal
medium for an additional 24h. Viability of cells was mea-
sured at this time (T0, corresponding to 48h after trans-
fection) and following 1, 3 or 5 days, as described in the
‘Materials and Methods’ section. It should be noted that
we have conﬁrmed, using ﬂuorescent oligonucleotides,
that more than 70% of re-seeded cells still contained
SRA–AS and bgl–AS (data not shown). As shown in
Figure 9, the number of viable cells remains identical
in cells treated without (Mock) or with a control oligo-
nucleotide (bgl–AS). In contrast, signiﬁcantly less viable
Figure 6. Western blot analysis of SRAP in T5 cells treated with
0.5mM SRA–AS. T5 cells were treated with 0.5mM of SRA–AS or
0.5mM bgl–AS. At t: 24, 48 and 72h, total were extracted and analyzed
by Western using anti-SRAP antibodies as described in ‘Materials and
Methods’ section. This Figure is representative of results obtained from
three independent experiments.
4524 Nucleic Acids Research, 2009, Vol. 37,No. 13cells are present at 1, 3 and 5d, which corresponds to 72,
120 and 168h following SRA–AS treatment, respectively.
DISCUSSION
The full sequencing of the human genome has led to a
growing interest in alternative splicing events. Indeed,
originally thought to possibly result from ‘hiccups’ of
the splicing machinery, it became evident that these
events are highly controlled and deﬁne a new level of com-
plexity in gene expression (23–26). The critical participa-
tion of alternative splicing in regulating normal major
biological events, such as sex determination or tuning of
brain receptor sensitivity, has been underlined in many
diﬀerent systems (27–29). It is now also suggested that
alteration of splicing can also be involved in many
Table 1. Change in gene expression at t: 24h following treatment of T5 cells with SRA–AS
Symbol Description CT Percentage expression P-value
PLAU Plasminogen activator, urokinase 2.87 729 0.021
ESR2 Estrogen receptor 2 (ER beta) 1.73 331 0.029
STC2 Stanniocalcin 2 1.20 230 0.009
JUN V-jun sarcoma virus 17 oncogene homolog (avian) 1.15 222 0.164
VEGF Vascular endothelial growth factor 0.98 197 0.034
SERPINA3 Serpin peptidase inhibitor, clade A, member 3 0.84 179 0.187
ID2 Inhibitor of DNA binding 2 0.72 165 0.234
THBS1 Thrombospondin 1 0.58 149 0.043
NGFR Nerve growth factor receptor 0.55 146 0.404
SLC7A5 Solute carrier family 7, member 5 0.45 137 0.433
DLC1 Deleted in liver cancer 1 0.43 134 0.202
KLF5 Kruppel-like factor 5 (intestinal) 0.43 134 0.369
CCNA2 Cyclin A2 0.33 125 0.223
CLDN7 Claudin 7 0.25 119 0.523
HMGB1 High-mobility group box 1 0.23 117 0.637
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) 0.20 115 0.620
ITGB4 Integrin, beta 4 0.12 109 0.642
TOP2A Topoisomerase (DNA) II alpha 170kDa 0.12 108 0.819
ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 0.07 105 0.898
MUC1 Mucin 1, transmembrane 0.05 104 0.834
TP53 Tumor protein p53 (Li-Fraumeni syndrome) 0.05 104 0.915
MKI67 Antigen identiﬁed by monoclonal antibody Ki-67 0.05 104 0.867
HPRT1 Hypoxanthine phosphoribosyltransferase 1 0.05 104 0.922
TFF1 Trefoil factor 1 0.03 102 0.951
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.00 100 1.000
ACTB Actin, beta – 100
CCND1 Cyclin D1 0.00 100 1.000
TGFA Transforming growth factor, alpha 0.00 100 1.000
RPL27 Ribosomal protein L27  0.03 98 0.959
PTEN Phosphatase and tensin homolog  0.03 98 0.902
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa  0.03 98 0.938
CLU Clusterin rotein J)  0.03 98 0.868
RPL13A Ribosomal protein L13a  0.03 98 0.894
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1)  0.05 97 0.830
ESR1 Estrogen receptor 1  0.05 97 0.878
NME1 Non-metastatic cells 1, protein (NM23A) expressed in  0.07 95 0.850
KRT19 Keratin 19  0.08 95 0.725
ITGA6 Integrin, alpha 6  0.08 94 0.869
SERPINE1 Serpin peptidase inhibitor, clade E, member 1  0.10 93 0.857
BCL2 B-cell CLL/lymphoma 2  0.10 93 0.797
CTSD Cathepsin D (lysosomal aspartyl peptidase)  0.14 91 0.740
GABRP Gamma-aminobutyric acid (GABA) A receptor, pi  0.15 90 0.760
CCNE1 Cyclin E1  0.17 89 0.473
KRT18 Keratin 18  0.18 89 0.660
GSN Gelsolin (amyloidosis, Finnish type)  0.20 87 0.706
CTSB Cathepsin B –0.22 86 0.654
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 –0.23 85 0.677
HSPB1 Heat shock 27kDa protein 1 –0.25 84 0.658
EGFR Epidermal growth factor receptor –0.26 84 0.222
GATA3 GATA-binding protein 3 –0.27 83 0.305
FAS Fas (TNF receptor superfamily, member 6) –0.35 78 0.142
NFYB Nuclear transcription factor Y, beta –0.43 74 0.102
IGFBP2 Insulin-like growth factor binding protein 2, 36kDa –0.43 74 0.357
CD44 CD44 antigen (Indian blood group) –0.47 72 0.148
BAG1 BCL2-associated athanogene –0.55 68 0.129
FLRT1 Fibronectin Leucine-rich transmembrane protein 1 –0.64 65 0.610
IL6R Interleukin 6 receptor –0.70 62 0.088
 Boldface depicts signiﬁcant P-values.
Nucleic Acids Research, 2009,Vol.37, No. 13 4525pathological situations including but not limited to skin
diseases (30), neurodegeneration (31), and cancer (32–37).
Interestingly, it has even been proposed that speciﬁc splic-
ing events may be associated to tissue speciﬁc cancer (38).
We have previously reported that diﬀerent breast cancer
cell lines grown in culture have diﬀerent relative levels of
coding/non coding SRA transcripts (12). This balance ulti-
mately controls two functional entities (SRA RNA and
SRAP) modulating the action of ER and PR, major
players in human breast tumorigenesis and tumor progres-
sion (39). It was critical to establish whether the relative
proportion of these transcripts diﬀered in vivo within
tumor tissues. The selected cohort consisted of tumors
with ER and PR values higher than 3 and 10fmol/mg of
total prot, respectively (40), therefore belonging to the
clinically established ER+/PR+ subgroup. This sub-
group has been selected as it represents the main subtype
of cases contained in the Manitoba Breast Tumor Bank
(MBTB). Indeed, within more than 5000 specimens col-
lected in the MBTB, 48% of tumors are ER+/PR+,
whereas 25%, 5% and 22% are ER+/PR ,E R  /PR+
and ER /PR , respectively.
Observed relative levels of non-coding intron-1-contain-
ing RNA varied from one sample to another, ranging
from 0.71 to 1.61a.u. (Figure 2C). Frozen tissue sections
analyzed are intrinsically heterogeneous, containing
cancer cells but also normal epithelial, ﬁbroblastic and
blood cells. These values could therefore represent an
average of the relative SRA transcripts expression within
all these cell types. These numbers are however fully con-
sistent with the ones obtained on isolated cancer cell lines
(between 0.80 and 2a.u. for MCF-10A1 cells and MDA-
MB-468 cells, respectively) (12). We have also shown that
SRA expression was higher in breast cancer tissue than in
normal breast tissue (41). The relative expression of SRA
transcripts assessed on tumor tissues therefore likely
reﬂects the balance coding/non coding SRAs in breast
cancer cells rather than in normal other cells contained
in these sections. However further in-situ experiments,
speciﬁcally highlighting individual SRA splicing variants,
are needed to conﬁrm this hypothesis.
Surprisingly, with such a small tumor subset, a signiﬁ-
cant higher relative intron-1-retention in tumors with
higher PR levels was identiﬁed. Indeed this suggests that
within these ER+/PR+ cases, the balance coding/non-
coding SRA transcript might characterize particular sub-
groups. It is well established that patients with ER+/
PR+ tumors have a higher chance to respond to endo-
crine therapy than other patients (42). It is also known
that within this group, higher ER and PR level are
associated with a better response to tamoxifen (40).
Unfortunately some patients, even though deﬁned
through ER and PR levels as most likely to beneﬁt, will
not respond to endocrine therapy. This reﬂects the heter-
ogeneous biology of tumors belonging to the currently
established ER+/PR+ subgroup and underscores the
need to further characterize these lesions to better predict
their behaviour upon treatment. It is believed that under-
standing the exact connections between traditional prog-
nostic/predictive factors, gene expression signatures
and patient outcome will allow the establishment of
more adequately targeted treatment (43). Our observation
that SRA intron-1 retention potentially characterizes a
particular tumor subgroup ﬁts with the current idea that
assessing alternative splicing events might help proﬁling
cancer sub-types (38,44–46).
We have herein successfully shifted the relative levels of
endogenous coding/non coding SRA transcripts in the
Figure 7. Change in gene expression in T5 cells following SRA–AS treatment. T5 cells were treated with 0.5mM of SRA–AS or 0.5mM bgl–AS as
described above. At t: 24h, RNA was extracted, reverse-transcribed, and used to assess, by real-time PCR, the expression of a series of 57 genes
historically linked to breast cancer, as described in the ‘Materials and Methods’ section. Four independent experiments were performed. Blue dots
represent, for each gene, the normalized expression upon bgl–AS treatment. Orange dots represent the average CT increase or decrease in gene
expression upon SRA–AS treatment. Bars represent the standard deviation for each gene and treatment. Genes whose expression is signiﬁcantly
modiﬁed (P<0.05, Student’s t-test, two-sided) upon SRA–AS treatment are indicated by orange stars.
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Our approach, consisted in masking a splicing donor site
with a modiﬁed oligonucleotide, and has been used suc-
cessfully by many diﬀerent groups to redirect splicing
events involving speciﬁc target RNAs (19,47–49). Such
an approach presents several advantages. As an anti-
sense method, it beneﬁts from the fact that 20-O-modiﬁed
(either methyl or methoxy-ethyl) oligoribonucleotide
phosphorothioates bind to pre-mRNA target sequences
in vivo with high speciﬁcity but do not form RNase H
competent RNA-oligonucleotide hybrid complexes (50).
Therefore, unlike more classical anti-sense oligonucleotide
techniques that result in mRNA degradation, these mod-
iﬁed anti-sense oligoribonucleotides are not expected to
Figure 8. Diﬀerential estrogen regulation of gene expression in T5 cells following SRA–AS treatment. T5 cells were treated with 0.5mMo fbgl–AS or
0.5mM SRA–AS as described earlier. Forty hours later, cells were treated for 4h by E2 10
 8M or vehicle (ethanol) alone, RNA was extracted,
reverse-transcribed, and assessed for the expression of a series of 57 genes as described in the ‘Materials and Methods’ section. Three independent
experiments were performed, and the expression of each gene normalized as detailed in the ‘Materials and Methods’ section. The average expression
of 15 genes upon E2 treatment (ﬁlled circle) and ethanol (hollow circle) are depicted. Bars represent standard deviation. (A) Cells have been treated
with 0.5mM bgl–AS. Genes expression of which is signiﬁcantly (p<0.05, Student’s t-test, two- sided) diﬀerent between E2 treatment and Ethanol, are
indicated by blue stars. (B) Cells have been treated with 0.5mM SRA–AS. Genes expression of which is signiﬁcantly (P<0.05, Student’s t-test, two-
sided) diﬀerent between E2 treatment and Ethanol are indicated by orange stars. (C) To visualize the diﬀerential eﬀect of E2 in cells treated with
SRA–AS (orange) and bgl–AS (blue), E2 corresponding dots from A and B have been plotted on the same graph. Genes whose expression is
signiﬁcantly (P<0.05, Student’s t-test, two-sided) diﬀerent upon E2 treatment are indicated by green stars.
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ative regulators that mask splice recognition sequences
thereby preventing recruitment of splicing factors. It
should however be noted that if a modiﬁcation of splicing
events is likely, a potential change in the stability of the
RNAs considered cannot be fully excluded. Applied to the
endogenous SRA RNA population, which ultimately con-
sists of fully-spliced coding, and intron-1 alternatively
spliced non-coding species, this strategy allows repro-
gramming the fate of immature RNAs toward the pro-
duction of more non-coding RNAs. Reprogramming
endogenous RNAs, as opposed to introducing exogenous
non-coding RNAs under the control of artiﬁcial pro-
moters such as the Cytomegalovirus promoter (CMV),
presents an obvious advantage to interrogate physiologi-
cal balance modiﬁcations. Treatment of cells with SRA–
AS oligoribonucleotides allowed the relative intron-1
retention levels to increase by a factor of 2.5-fold. This
increase is very similar to the diﬀerence previously
observed (2-fold) between MDA-MB-468 invasive breast
cancer cells and T5 non-invasive breast cancer cells (12).
This conﬁrms the suitability of the approach to increase
the relative proportion of non-coding SRA RNA up
to levels naturally occurring in the various cell lines pre-
viously characterized.
We herein showed that the increase (2.5-fold) in the
relative amount of intron-1 retained SRA RNA as
assessed by TP-PCR corresponded, using real-time PCR,
to an absolute increase of  90% of this transcript and a
 70% decrease of fully spliced SRA RNA (Figure 5). As
expected, the decrease in coding SRA RNA resulted in a
decrease in endogenous SRAP levels detected by Western
blot (Figure 6). This underscores that whatever eﬀects of
SRA–AS oligonucleotide treatment might be, they may
result from either the increase in non-coding functional
SRA transcript, or a decrease in protein function or both.
PLAU (plasminogen urokinase activator also called
uPA), is known to play a critical role in the develop-
ment of metastases through the activation of several
metalloproteinase (22,51) and was among the genes
whose expression was modiﬁed after SRA–AS oligonu-
cleotide treatment. Interestingly, we have previously
reported that invasive MDA-MB-231 and MDA-MB-
468 breast cancer cells expressed signiﬁcant more SRA
RNAs retaining intron-1 than non-invasive MCF-7,
T47D or BT20 cells, whereas the more ‘normal’ MCF-
10A1 breast cell line expressed the lowest relative level
of SRA intron-1 RNA (12). This suggests that a balance
‘tipped’ toward the production of non-coding SRA1 RNA
in breast cells might aﬀect growth and/or invasion proper-
ties. Altogether, this observation suggests that non-coding
SRA RNA, through the over-expression of genes such as
PLAU, might directly participate in the establishment
of an invasive phenotype in breast cancer cells. Further
studies are needed to corroborate this hypothesis.
A signiﬁcant increase in ESR2, and to a lesser extend in
Stanniocalcin 2, Vascular endothelial growth factor and
Thrombospondin 1 expression were observed upon SRA–
AS treatment. All these genes have previously been
shown to be up-regulated by estrogens in breast cancer
cells (52–54). Their altered expression following the artiﬁ-
cial shift in endogenous coding/non-coding SRA tran-
scripts outline the relevance of this balance in mediating
estrogen eﬀects in breast cancer cells. Interestingly,
increasing the relative levels of non-coding SRA had dis-
tinct potential eﬀects on estrogen mediated gene regula-
tion. For genes such as Bcl2, THSB1, TFF1, TGFA,
DLC1 the signiﬁcant and previously described estrogen
induced over-expression (55–58) remains signiﬁcant
(Figure 8A and B). This could result from an absence of
eﬀect of SRA RNA and SRAP on the estrogen regulation
of these particular genes. As outlined earlier, our
approach modiﬁes both functional RNA and protein
levels. This lack of eﬀect could therefore also reﬂect a
neutralization of opposite individual actions. For genes
like CTSD or MUC1, the respective trend toward an
increase or a decrease in expression upon estrogen treat-
ment becomes signiﬁcant (Figure 8A and B). This ampli-
ﬁcation of estrogen action ﬁts with the concept that
increasing the relative levels of the functional non-
coding RNA co-activator enhances estrogen receptor
activity. It should however be noted that for these genes,
no signiﬁcant diﬀerences in estrogen eﬀect is observed
upon modifying coding/non-coding SRA transcripts
(Figure 8C). Additional time-course experiments as well
as experiments designed to investigate the respective
actions of non-coding SRA and SRAP are needed to fur-
ther characterize the eﬀect the balance of coding/non-
coding transcripts plays on the estrogen regulation of
these genes.
Most interestingly, altering the balance of coding/non-
coding SRA signiﬁcantly disrupts estrogen’s eﬀect on
NME1, CTNNB1, KRT18, Fas and FLRT1 genes
(Figure 8C). CTNNB1 or beta catenin, an inherent
component of the Wnt/b-Catenin canonical signalling
pathway, is a critical player in development as well
as cell–cell contact and migration processes (59–61).
Figure 9. Diﬀerential viability of T5 cells following SRA–AS treatment.
Cells were treated with SRA–AS (orange), bgl–AS (blue) or without
(Mock, Black) oligonucleotides, re-seeded in 96 wells plates after 24h
and allowed to grow in normal medium for an additional 24h. At this
time (T0), or 1 (1d), 3 (3d) and 5 (5d) days later, the amount of live
cells was determined and expressed in arbitrary unit as described in the
‘Materials and Methods’ section. For each point, the mean and the
standard deviation corresponding to two independent experiments,
each performed in quadruplicate, are indicated. Stars indicate a signif-
icant (P<0.05) diﬀerence between SRA–AS and both negative controls
(bgl–AS and Mock), as assessed by the Student’s t-test, two-tailed.
4528 Nucleic Acids Research, 2009, Vol. 37,No. 13NME1 (non-metastatic cells 1), whose expression is regu-
lated by estradiol in breast cancer cells (62), is also
believed to itself modulate estrogen receptor alpha
action (63). These results overall suggest that relative
levels of SRA transcripts still containing intron-1 have
the potential to control selectively estrogen eﬀect on spe-
ciﬁc genes highly relevant to development and cancer.
Further experiments are warranted to establish the exact
mechanisms behind these eﬀects and to assess the full
extent of the impact of the balance of SRA transcripts
on estrogen action.
We have herein used a colorimetric method for deter-
mining the number of viable cells following modiﬁcation
of the balance of endogenous SRA towards the produc-
tion of more non-coding transcripts. It should be stressed
that the number of viable cells at a given time is a direct
result of cell proliferation and cell death. Our experiments
strongly suggest that the balance of coding/non-coding
transcripts participates to the growth of breast cancer
cells. Indeed, compared to both our controls, less viable
cells are present following SRA–AS treatment. We cannot
however, at the present stage, establish whether enhancing
the relative amount of non-coding SRA RNA increases
apoptosis or decreased cell proliferation. Additional
experiments are needed to address this issue.
Herein, we have shown that the balance of coding/non-
coding SRA RNAs could be altered through the use of
modiﬁed oligoribonucleotides in breast cancer cells. This
led to a change in expression of genes likely to have an
important impact on two critical aspects of breast cancer
cell phenotype, namely invasion and response to estrogen.
It also led to a decrease in cell growth/viability. It has been
previously hypothesized that strategies aimed at favouring
the production of a given splice variant could be devel-
oped and proposed as new therapeutic tools (64–66). We
propose that modifying SRA splicing events might lead to
establishing potential new breast cancer treatments.
While SRA remains one the best characterized
bi-functional RNA to date, other studies have highlighted
the existence of similar other cases (67–69). Such systems,
even though they challenge the paradigm classifying RNA
as either strictly coding or as non–coding, provide a
unique opportunity to further explore the mechanisms
used by nature to control gene expression. There is an
urgent need to design new experimental approaches to
address the respective functions of these peculiar
bi-faceted RNAs.
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